Log in or register
Share on LinkedInShare on LinkedIn

ARTICLE · 08 OCTOBER 2025

First Drug Patent Term Extension Granted In China

Toby Mak
Explore more from Toby Mak

With the information from Chenghua Luo of Amgen , which is highly appreciated, I write to report on the first drug patent term extension (DPTE) granted in China. Please correct me if anyone is aware of another DPTE granted in China earlier.

ChinaIntellectual Property
Toby Mak
Toby Mak

With the information fromChenghua LuoofAmgen, which is highly appreciated, I write to report on the first drug patent term extension (DPTE) granted in China. Please correct me if anyone is aware of another DPTE granted in China earlier.

The drug at issue is spesolimab, branded Spevigo IV fromBoehringer Ingelheim(BI), which is a humanized IgG1 monoclonal antibody treating Generalized Pustular Psoriasis (GPP, a nasty and potentially life-threatening disease characterized by widespread, sterile, pus-filled blisters) by blocking the activation of the interleukin-36 receptor. Information on this DPTE (see attached) is as below:

  • The China National Medical Products Administration (NMPA) granted the drug marketing approval (DMA) to Spevigo IV on 13 December 2022 as a class 1 innovative drug.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

Register for freeORLog in

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Related Articles

Legal Intelligence Newsletters: sign up for the latest legal and regulatory news on your chosen topics

Read more about

Related Comparative Guides

See more popular content from

Article

China's Supreme Court Issues Landmark Judicial Rules On AI: Implications For Product Liability, IP, Data, And Generative AI

China's Supreme People's Court has issued comprehensive judicial rules addressing artificial intelligence disputes, establishing frameworks for product liability, intellectual property rights, and data protection. These landmark opinions provide critical guidance for global companies navigating AI-related legal risks in China's evolving regulatory landscape.
ChinaIntellectual Property
Jones Day
Jones Day